The following stocks are the leading risers and fallers on AIM in London on Wednesday.
----------
AIM - WINNERS
----------
Parkmead Group PLC, up 17% at 49.80 pence, 12-month range 34.40p-64.40p. The Netherlands and UK-focused gas explorer says its assets ‘continue to perform well’. It has benefitted from surging gas prices in Europe. As a result, it expects annual gas revenue, from its Dutch assets, to exceed €14.5 million for the year ended June - which is ahead of internal expectations.
----------
Surface Transforms PLC, up 7.0% at 46.53 pence, 12-month range 36.00p-70.50p. The Liverpool-based manufacturer of carbon fibre reinforced ceramic materials is ‘confident’ it can achieve profit in 2022. Revenue in the first half of the year surges to £2.9 million from £1.2 million a year earlier, thanks in part to deliveries on the Aston Martin Lagonda Holdings PLC Valkyrie sports car project.
----------
AIM - LOSERS
----------
Attraqt Group PLC, down 12% at 22.00p, 12-month range 21.91p-45.00p. The London-based provider of online search, merchandising and personalisation solutions for e-commerce expects a weakening economic outlook to ‘delay some customer decisions’ and lengthen enterprise sales lead times. However, the company adds that revenue for the first half of 2022 rises 8% year-on-year at constant currency to £12.1 million.
----------
Hutchmed (China) Ltd, down 4.6% at 240.50p, 12-month range 1.38p-247.00p. The stock falls as tens of millions more people are put under lockdown in China on Wednesday as businesses in a major tourist city are forced to shut their doors and fresh clusters sparked fears of a return to blanket restrictions. Health authorities have reported over 300 infections Wednesday, with clusters found in the historic northern city of Xi’an – home to the Terracotta Army – as well as the country’s biggest city Shanghai. Also on Wednesday, Hutchmed says it has dosed a first patient for its phase I trial for IMG-007. The Hong Kong-based biopharmaceutical firm said the trial will test the investigational OX40 antagonistic monoclonal antibody for the treatment of moderate to severe atopic dermatitis.
----------
Copyright 2022 Alliance News Limited. All Rights Reserved.
